MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Dynavax Technologies Corporation Total Assets 2011-2026 | DVAX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 986 M | 997 M | 986 M | 1.04 B | 353 M | 279 M | 211 M | 219 M | 110 M | 217 M | 138 M | 205 M | 140 M | 134 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.04 B | 110 M | 430 M |
Quarterly Total Assets Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 947 M | 918 M | 946 M | 986 M | 1.06 B | 1.02 B | 987 M | 997 M | 973 M | 936 M | 970 M | 986 M | 999 M | - | 1.01 B | 1.04 B | 920 M | 648 M | 490 M | 353 M | 353 M | 353 M | 353 M | 279 M | 279 M | 279 M | 279 M | 211 M | 211 M | 211 M | 211 M | 219 M | 219 M | 219 M | 219 M | 110 M | 110 M | 110 M | 110 M | 217 M | 217 M | 217 M | 217 M | 138 M | 138 M | 138 M | 138 M | 205 M | 205 M | 205 M | 205 M | 140 M | 140 M | 140 M | 140 M | 134 M | 134 M | 134 M | 134 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.06 B | 110 M | 428 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K |  USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
220 M | $ 3.01 | 3.79 % | $ 233 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.08 B | $ 11.29 | -3.01 % | $ 730 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.99 | 1.02 % | $ 508 M | Britain |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 213.24 | 1.86 % | $ 5 B |  Danmark |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
BioVie
BIVI
|
21.6 M | $ 1.16 | 2.65 % | $ 1.71 M | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Certara
CERT
|
1.58 B | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Celldex Therapeutics
CLDX
|
792 M | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 95.2 | -0.08 % | $ 27.2 B | Germany |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cellectis S.A.
CLLS
|
384 M | $ 4.84 | 1.26 % | $ 116 M | France |
 |
Cellectar Biosciences
CLRB
|
12.1 M | $ 2.95 | 7.66 % | $ 36.1 M | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
841 M | $ 34.8 | -50.42 % | $ 3.59 B | USA |
 |
Axon Enterprise
AXON
|
4.47 B | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Checkpoint Therapeutics
CKPT
|
7.47 M | - | - | $ 169 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |